• "Biotech where science and spirit meet..."
Skip to content

{ Category Archives: } Coronavirus

Eli Lilly’s COVID-19 antibody shows it can prevent the disease. But will doctors use it?

Eli Lilly’s bamlanivimab was the first antibody drug the FDA authorized to treat COVID-19. Now, the Indianapolis pharma has data showing the therapy prevents symptomatic infections. The catch? The data are limited to long-term care facilities, where vaccination is now underway—and despite their utility, antibody thereapies are having a tough time catching on. Bamlanivimab cut the…

JPM: Regeneron execs say ‘it’s a problem’ how few COVID-19 patients are getting antibody treatments

To Regeneron, there’s no question about it: “We as a society have to do a much better job” of getting antibody therapies—such as the company’s own—to patients, R&D chief George Yancopoulos said Monday at the J.P. Morgan Healthcare Conference. Like Eli Lilly’s single-antibody treatment, Regeneron’s antibody cocktail bears an emergency use authorization in mild-to-moderate COVID-19 patients at…

Here’s Why Inovio Is The Front-Runner In Developing a Coronavirus Vaccine

As of July 12, the number of new cases of COVID-19 in the U.S. has surpassed 60,000 for the fifth day in a row. Unfortunately, this rise cannot be attributed to increases in testing. For most of last week, nearly 1,000 Americans died each day due to COVID-19, representing a 300% increase from the death…

Biotech GSK gives Clover adjuvant for vaccine against ‘indispensable’ COVID-19 protein

GlaxoSmithKline has struck a deal to provide its pandemic adjuvant to Clover Biopharmaceuticals for use in a COVID-19 vaccine candidate. Clover is one of a clutch of organizations working to tackle COVID-19 by targeting a protein the novel coronavirus needs to enter host cells. China’s Clover, which is based 600 miles west of the focal point of…